Article

Vial launches VialConnect: Modernized CTMS with patient recruitment assistance

The company's VialConnect is an intuitive clinical trials management platform built for coordinators and investigators.

Vial this week announced the debut of VialConnect, an intuitive clinical trials management platform built for coordinators and investigators.

According to the company, VialConnect is offered at no cost and makes it simple for research sites to access Vial’s modernized CTMS and additional services for patient recruitment.

The company noted in a news release that signing up for VialConnect gives sites access to 2 services for free: First, a customizable CTMS (clinical trials management system) that powers core workflows and provides operational visibility. And second, A HIPAA-compliant EMR filtering tool making it easier to sort potential trial subjects.

"Since implementing Vial's CTMS at our sites, our team's day-to-day operations have become faster and more efficient,” Stacey Gomez, a clinical research manager and one of the first users said in a statement. “We can easily schedule new appointments, track patients, and view all of our studies in one place. It's easy to navigate and our team loves it.”

Simon Burns, co-founder and CEO of Vial, noted that the company talked extensively with PIs and CRCs to identify their main pain points — the lack of an intuitive CTMS and an inability to recruit patients efficiently.

VialConnect solves these issues through modernized tech solutions,” he said in the release. “After deploying VialConnect at our 30+ partner sites, it’s clear from their feedback that our CTMS and patient recruitment program wins in all of these areas.”

Vial strives to be a next generation site management organization by providing the necessary resources for research practices to run trials with faster execution and higher quality.

The company has over 90 employees and is based in San Francisco, California.

Related Videos
AAO 2024: Matt Giegengack, MD: Injectable endothelial cell therapy shows promise for improving vision and reducing glare in corneal edema
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
Arun Gulani, MD: How the Gni instrument enhances precision and control in cataract surgery
EyeCon 2024: Laura M. Periman, MD, shares her passion for dry eye disease, discussing her surprising discovery of the Alpenglow Sign in Demodex blepharitis
David Eichenbaum, MD, presents advances in AMD therapy, highlights different mechanisms with a common goal
Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry
© 2024 MJH Life Sciences

All rights reserved.